Published in Vaccine Weekly, November 9th, 2005
The objectives of the trial are to evaluate the safety, toxicity, pharmacokinetic profile and initial clinical activity of KP-1461. The trial is being conducted at several HIV treatment centers in the United States.
KP-1461 is a first-in-class therapeutic designed to overcome the problem of drug resistance that has emerged with approved HIV treatments. KP-1461 has a novel mechanism of action designed to eliminate the human immunodeficiency virus (HIV) by selectively increasing its natural mutation rate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly